Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia
Abstract Current treatment of severe epistaxis in patients with hereditary hemorrhagic telangiectasia is not durable in reducing the frequency and severity of bleeds. Recent reports have demonstrated marked improvement of…